Table 1 General characteristics of kidney transplant recipients
From: Prevalence of vancomycin-resistant Enterococcus fecal colonization among kidney transplant patients
Number of Patients | 280 (100) |
|---|---|
Group 1 (less than 30 days after transplantation) | 102 (36.4) |
Group 2 (1 to 6 months after transplantation) | 73 (26) |
Group 3 (> 6 months after transplantation) | 105 (37.5) |
Gender | |
Male | 163 (58.2) |
Race | |
White | 187 (66.7) |
Non-white | 93 (33.2) |
Primary renal disease | |
Indeterminate | 137 (48.9) |
Hypertension | 61 (21.7) |
Glomerulonephritis | 44 (15.7) |
Diabetes Mellitus | 11 (3.9) |
Others | 27 (9.6) |
Pre transplant treatment | |
Hemodialysis | 262 (93.5) |
CAPD | 12 (4.2) |
Conservative | 6 (2.1) |
Kidney donor | |
HLA I and II | 160 (57.1) |
HLA III and deceased donor | 120 (42.8) |
Immunosuppressive drugs ** | |
Mycophenolate mofetil | 59 (33.1) |
OKT3/Thymoglobulin® | 13 (7.3) |
Methylprednisolone pulse | 58 (32.5) |
Surgical reexploration | 14 (5) |
Post-transplantation dialysis | 46 (16.4) |
Serology | |
Hepatitis C virus | 31 (11) |
Hepatitis B virus | 7 (2.5) |
Post-transplantation antimicrobial drugs ** | 117 (65.7) |
Vancomycin ** | 11 (6.1) |
Ganciclovir ** | 18 (10.1) |